AME vs ROP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ROP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AME and ROP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AME and ROP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume.

Full AME guide

Roper Technologies has spent the past decade reinventing itself from an industrial tools and equipment maker into a diversified holding company whose center of gravity is vertical-market software. It operates through three segments: Application Software (businesses like Deltek for government contractors, Vertafore in insurance, Aderant for law firms, Frontline in K-12 education, and Clinisys in diagnostics), Network Software (network-effect platforms such as DAT in freight and iPipeline in insurance), and Technology Enabled Products (Neptune water meters, Verathon and CIVCO in medical devices). More than half of total revenue is now recurring, coming from SaaS subscriptions, maintenance and transaction fees, and application plus network software together generate roughly three-quarters of revenue.

Full ROP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AME drivers: Record orders tied to AI infrastructure, aerospace and defense; The $5 billion Indicor instrumentation acquisition.
• ROP drivers: Acquisition-driven compounding; Recurring, high-margin software mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most immediate risk: at roughly 37 times trailing and about 29 times forward earnings, with an EV/EBITDA near 24, the shares price in continued execution and leave limited room for a demand air pocket. For ROP, the clearest risk is valuation: ROP trades at a premium multiple, so disappointing results or a slower deal pace can compress the stock even if the business stays healthy.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AME if you believe its drivers more; ROP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AME and ROP guides.

AME. AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 37, a forward P/E near 29 and EV/EBITDA around 24. The premium reflects roughly 26 percent operating margins, about $1.8 billion of free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares were near $254 in early August 2026 against a 52-week range of roughly $179 to $258, so recent record results and the raised guidance are largely reflected in the price.

ROP. Roper's Q1 2026 revenue rose about 11% year over year to roughly $2.10 billion, split between 6% organic growth and 5% from acquisitions, and it raised full-year adjusted earnings guidance while adding to its buyback authorization. Net margins sit near 19% to 20% and adjusted EBITDA margins around 38%, reflecting the software-heavy mix. The forward multiple in the mid-to-high teens is well below the stock's longer-run median, which bulls read as more reasonable and bears view as still-full for a business dependent on ongoing M&A.

Headline figures (approximate, August 2026): AME shows revenue (ttm) ~$7.86B, up ~12.7%, net income (ttm) ~$1.58B (~20% margin), q2 2026 sales / adj. eps ~$2.04B (+15%) / ~$2.09, 2026 adj. eps guidance ~$8.20 to $8.30; ROP shows revenue (ttm) ~$8.0 billion, q1 2026 revenue ~$2.10 billion (up ~11% YoY), market cap ~$35-36 billion, fy2026 adjusted deps guidance ~$21.80-$22.05.

AME and ROP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AME and ROP exposure against your real portfolio. It is not an investment adviser.